Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 524 people in the ZD4054 plus docetaxel (chemotherapy) group and 528 people in the placebo plus docetaxel group — just over 1,050 participants in total. The trial was looking at men with prostate cancer, and it was measuring things like how long people lived overall, how long it took for the cancer to get worse, and whether they experienced bone-related complications or changes in pain levels. The reported data shows that for overall survival — the main thing the trial was measuring — the median time from the start of the trial until death was 20.0 months in the ZD4054 group and 19.2 months in the placebo group. (Median means half of the participants in each group lived longer than this, and half did not.) For the secondary measures: the median time until the cancer progressed was 7.0 months versus 7.9 months; the median time until a bone-related event (such as a fracture or spinal complication) was 17.4 months versus 17.3 months; the median time until a PSA blood marker rose significantly was 11.9 months versus 12.1 months; and the median time until pain worsened was 9.3 months versus 10.0 months. For pain response — the number of people whose pain scores or painkiller use decreased — 255 participants in the ZD4054 group and 276 in the placebo group recorded a response. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Prostate Cancer Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with prostate cancer that has spread to the bones.
- Your PSA (a protein measured by a blood test used to monitor prostate cancer) levels have been rising, with a test result taken within the last year.
- You are currently being treated to lower testosterone levels, either through surgery or medication.
Who may not be able to join:
- You have previously been treated with certain chemotherapy drugs (paclitaxel, docetaxel, or mitoxantrone) — note that some other targeted cancer treatments received as part of a previous clinical trial are allowed (confirm with trial site).
- You have heart failure, or you have had a heart attack in the last 6 months.
- You have a history of epilepsy or seizures.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Overall Survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.